“Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms.

PURPOSE:

The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.” https://www.ncbi.nlm.nih.gov/pubmed/29745439 https://onlinelibrary.wiley.com/doi/abs/10.1111/nmo.13370]]>